UNIVERSITY OF MINNESOTA

Eledon Pharmaceuticals will present updated clinical data from approximately 30 kidney transplant recipients in their ongoing Phase 1b study of tegoprubart at the World Transplant Congress in San Francisco.

Trichoscopy enables clinicians to differentiate between scarring and non-scarring alopecia by identifying specific patterns such as scale adherence to hair fibers and loss of follicular ostia.

Acerand Therapeutics has dosed the first patient in a Phase I clinical trial of ACE-232, a novel oral CYP11A1 inhibitor for metastatic castration-resistant prostate cancer.

Mycovia Pharmaceuticals has enrolled the first participant in the PLATFORM-CM Phase 2 trial evaluating oteseconazole for cryptococcal meningitis treatment.

Eton Pharmaceuticals announced FDA approval of KHINDIVI (hydrocortisone) oral solution, marking the first and only FDA-approved liquid hydrocortisone formulation for pediatric patients aged 5 and older with adrenocortical insufficiency.

GT Biopharma has successfully completed dosing in the first cohort of its Phase 1 trial for GTB-3650, a second-generation TriKE immunotherapy, with no safety or tolerability issues observed.

A 35-year-old woman with stage 4 colon cancer achieved complete remission after receiving experimental CRISPR-Cas9 gene-edited immunotherapy at the University of Minnesota, marking an unprecedented outcome for advanced colorectal cancer.

University of Minnesota researchers conducted the first human trial using CRISPR/Cas9 to modify immune cells, demonstrating safety and potential effectiveness against advanced gastrointestinal cancers.

The American Heart Association has funded seven research projects with $1 million to identify which patients with obesity and cardiovascular disease benefit most from GLP-1/GIP medications.

• A new study published in Nature Communications Medicine reveals that 91.5% of tinnitus patients experienced clinically meaningful improvement after 12 weeks of treatment with the Lenire bimodal neuromodulation device. • The retrospective analysis of 220 patients represents one of the largest real-world studies of tinnitus treatment, confirming results from previous clinical trials that led to FDA approval in March 2023. • Lenire works by simultaneously delivering audio tones through headphones and mild electrical pulses to the tongue, offering a promising treatment option for the estimated 25 million Americans suffering from tinnitus.